University of Missouri researchers have found that luteolin, a natural compound found in herbs such as thyme and parsley, and vegetables such as celery and broccoli, could reduce the risk of developing metastasis originating from triple–negative breast cancer in women.

Hyder and his research team have focused on luteolin, a naturally occurring, non–toxic plant compound that has been proven effective against several types of cancer. Using human triple–negative breast cancer cells grown in mice, the research team tested luteolin to determine if it could suppress metastasis. In the first series of tests, researchers found that luteolin inhibited the metastasis of triple–negative cancer in the lungs of affected mice.

“Mice exposed to human triple–negative breast cancer cells experienced significantly reduced metastastic growth in their lungs after being treated with luteolin,” Hyder said. “In almost every case, the mice also saw no weight loss, which means luteolin has no toxic effects; this plant compound is both safe and effective.”

Hyder further tested luteolin and its effects on subduing the migration of triple–negative breast cancer cells throughout the body. The research team tested the cells in dishes that were treated with luteolin and found that migration was inhibited by the plant compound.

“Triple–negative breast cancer cells are highly mobile in the body, which helps them metastasize to other organs throughout the body,” Hyder said. “We found that luteolin inhibits that migration and also can kill cancer cells. We contend that these studies support further investigation of luteolin as an anti–metastatic agent that could be used to combat triple–negative breast cancer and its metastasis.”

The early–stage results of this research are promising. If additional studies are successful within the next few years, MU officials will request authority from the federal government to begin human drug development (this is commonly referred to as the “investigative new drug” status). After this status has been granted, researchers may conduct human clinical trials with the hope of developing new treatments for triple–negative breast cancer in women.

Researchers involved with the study included Matthew T. Cook, a recent doctoral graduate and research scientist at Dalton Cardiovascular Research Center; Cynthia Besch–Williford, professor of veterinary pathobiology; and Yayun Liang, a research associate professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center at MU.

The study, “Luteolin inhibits lung metstasis, cell migration, and viability of triple–negative breast cancer cells,” recently was published in the journal Breast Cancer – Targets and Therapy with funding provided through the College of Veterinary Medicine Committee on Research and through the generosity of donors to the Ellis Fischel Cancer Center at MU.